Drug Trial Radar · NCT06347458
BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Children
Last checked: Nov 19, 2026Latest source record: Apr 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Apr 2024
Primary completion
Apr 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- Guangzhou Bio-gene Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 3 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-arm, single-dose dose-escalation and dose-expansion study.
Conditions
- Leukemia
- Acute Myeloid Leukemia
Interventions
BG1805Biological
A single infusion of BG1805 Injection administered intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 1.Dose Limited Toxicity RateTime frame: Up to 28 days after BG1805 infusion.
- 2.Incidence of Treatment-Emergent Adverse EventsTime frame: Up to 24 months.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.